Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-028587
Filing Date
2018-11-08
Accepted
2018-11-08 16:35:01
Documents
73
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q akba-10q_20180930.htm 10-Q 2356521
2 EX-31.1 akba-ex311_6.htm EX-31.1 17694
3 EX-31.2 akba-ex312_10.htm EX-31.2 17694
4 EX-32.1 akba-ex321_7.htm EX-32.1 12255
5 EX-99.1 akba-ex991_9.htm EX-99.1 129529
6 GRAPHIC g1ife3apv54d000001.jpg GRAPHIC 28819
  Complete submission text file 0001564590-18-028587.txt   10157503

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT akba-20180930.xml EX-101.INS 2553228
8 XBRL TAXONOMY EXTENSION SCHEMA akba-20180930.xsd EX-101.SCH 70996
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE akba-20180930_cal.xml EX-101.CAL 50478
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE akba-20180930_def.xml EX-101.DEF 255280
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20180930_lab.xml EX-101.LAB 451906
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20180930_pre.xml EX-101.PRE 387682
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 181170173
SIC: 2834 Pharmaceutical Preparations